The Prognostic Significance of Minimal Residual Disease in Multiple Myeloma in the Molecular Genetic Groups Msmart 3.0

被引：0
|
作者：
Garifullin, Andrey
Voloshin, Sergei
Linnikov, Sergey
Martynkevich, Irina
Kuvshinov, Alexey
Kuzyaeva, Anastasiya
Chubukina, Zhanna
Shuvaev, Vasily
Kleina, Elizaveta
Bakai, Marina
Hmidt, Alexander S.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-139239
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma
    Paiva, Bruno
    Chandia, Mauricio
    Puig, Noemi
    Vidriales, Maria-Belen
    Perez, Jose J.
    Lopez-Corral, Lucia
    Ocio, Enrique M.
    Garcia-Sanz, Ramon
    Gutierrez, Norma C.
    Jimenez-Ubieto, Ana
    Lahuerta, Juan-Jose
    Mateos, Maria-Victoria
    San Miguel, Jesus F.
    HAEMATOLOGICA, 2015, 100 (02) : E53 - E55
  • [42] Individual molecular monitoring of minimal residual disease after autotransplantation in patients with multiple myeloma
    Zherebtsova, V.
    Surin, V.
    Savchenko, V.
    Mendeleeva, L.
    Pokrovskaya, O.
    Turina, N.
    Misurin, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S143 - S143
  • [43] The prognostic significance of cytogenetics and molecular profiling in multiple myeloma
    Sawyer, Jeffrey R.
    CANCER GENETICS, 2011, 204 (01) : 3 - 12
  • [44] Prognostic Significance of Minimal Residual Disease Testing by Multiparameter Flow Cytometry in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
    Mostafa, Nevine
    El-Salakawy, Walaa
    Abdelbary, Haitham
    Radwan, Rania
    Fathy, Rasha
    Abouelmagd, Yasmin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S300 - S300
  • [45] Minimal residual disease following autologous stem cell transplant for myeloma patients in the Myeloma XI trial: prognostic significance and the impact of lenalidomide maintenance and molecular risk
    De Tute, Ruth
    Pawlyn, Charlotte
    Cairns, David
    Davies, Faith
    Rawstron, Andy
    Jones, John
    Hockaday, Anna
    Menzies, Tom
    Henderson, Rowena
    Cook, Gordon
    Drayson, Mark
    Jenner, Matthew
    Kaiser, Martin
    Gregory, Walter
    Morgan, Gareth
    Jackson, Graham
    Owen, Roger
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S10 - S10
  • [46] Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
    Charalampous, Charalampos
    Kourelis, Taxiarchis
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [47] Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
    Kothari, Shalin
    Hillengass, Jens
    McCarthy, Philip L.
    Holstein, Sarah A.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (01) : 39 - 46
  • [48] The role of minimal residual disease evaluation for patients with multiple myeloma
    Eun, Yoon Sang
    Kim, Hyun-Young
    Cho, Duck
    Kim, Seok Jin
    Kim, Kihyun
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S80 - S80
  • [49] Multiple myeloma patient perceptions of minimal residual disease testing
    Hydren, Jay
    Martinez, Jorge Arturo Hurtado
    Quiroz, Felipe Flores
    Perez, Patricia Alejandra Flores
    Espinoza, Andrea Isabel Robles
    Vicencio, Andrea Jimena Cuevas
    Flores, Marilu Najera
    Hernandez, Eduardo Franco
    Aldana, Ana Sahagun Sanchez
    Sweeney, Nathan
    Ahlstrom, Jennifer
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S74 - S74
  • [50] Progress in the application of minimal residual disease detection in multiple myeloma
    Xiaojia Zuo
    Dingsheng Liu
    Journal of Hematopathology, 2021, 14 : 97 - 107
12345